Edition:
India

Aeglea Bio Therapeutics Inc (AGLE.OQ)

AGLE.OQ on NASDAQ Stock Exchange Global Market

8.86USD
1:30am IST
Change (% chg)

$-0.13 (-1.45%)
Prev Close
$8.99
Open
$8.94
Day's High
$9.02
Day's Low
$8.61
Volume
38,090
Avg. Vol
75,127
52-wk High
$12.00
52-wk Low
$3.75

Latest Key Developments (Source: Significant Developments)

Aeglea Biotherapeutics Announces Positive Interim Clinical Data
Wednesday, 17 Oct 2018 

Oct 17 (Reuters) - Aeglea Bio Therapeutics Inc ::AEGLEA BIOTHERAPEUTICS ANNOUNCES NEW POSITIVE INTERIM CLINICAL DATA AND IMPROVEMENTS IN DISEASE MANIFESTATIONS FOR ONGOING PHASE 1/2 TRIAL OF PEGZILARGINASE IN PATIENTS WITH ARGINASE 1 DEFICIENCY.AEGLEA BIO THERAPEUTICS INC - CLINICALLY SIGNIFICANT IMPROVEMENTS AFTER EIGHT DOSES INCLUDED EFFECTS ON MOBILITY AND ADAPTIVE BEHAVIOR.AEGLEA BIO THERAPEUTICS INC - PEGZILARGINASE IS EFFECTIVE IN SUSTAINABLY LOWERING PLASMA ARGININE LEVELS.AEGLEA BIO THERAPEUTICS INC - PEGZILARGINASE WAS WELL TOLERATED.  Full Article

Aeglea Biotherapeutics Appoints President And Chief Executive Officer
Friday, 20 Jul 2018 

July 19 (Reuters) - Aeglea Bio Therapeutics Inc ::AEGLEA BIOTHERAPEUTICS APPOINTS DR. ANTHONY G. QUINN AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.AEGLEA BIO THERAPEUTICS INC - QUINN HAS BEEN A MEMBER OF COMPANY'S BOARD OF DIRECTORS SINCE 2016 AND HAD SERVED AS INTERIM CEO SINCE JULY 2017.  Full Article

Aeglea Biotherapeutics Prices Public Offering Of Common Stock
Thursday, 19 Apr 2018 

April 18 (Reuters) - Aeglea Bio Therapeutics Inc ::AEGLEA BIOTHERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 4.50 MILLION COMMON SHARES PRICED AT $8.00PER SHARE.  Full Article

Aeglea Biotherapeutics Q4 Revenue $1.5 Mln Vs $1.2 Mln
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Aeglea Bio Therapeutics Inc ::AEGLEA BIOTHERAPEUTICS PROVIDES KEY CLINICAL DATA UPDATE FROM PHASE 1/2 TRIAL IN ARGINASE 1 DEFICIENCY AND REPORTS Q4 AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 REVENUE $1.5 MILLION VERSUS $1.2 MILLION.Q4 REVENUE VIEW $1.2 MILLION -- THOMSON REUTERS I/B/E/S.‍REPEAT DOSES OF COMPANY'S PEGZILARGINASE PRODUCES MARKED AND SUSTAINED REDUCTIONS IN PLASMA ARGININE LEVELS​.‍ACCOMPANYING REDUCTIONS IN OTHER RELATED GUANIDINO COMPOUNDS ALSO SEEN IN STUDY​.‍EXPECTS TO REPORT PEDIATRIC AND ADULT REPEAT DOSE DATA IN PATIENTS WITH ARGINASE 1 DEFICIENCY IN Q3 2018​.AEGLEA BIO - ‍AS OF DEC 31, 2017, HAD AVAILABLE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $50.3 MILLION​.AEGLEA BIO THERAPEUTICS - BASED ON CURRENT OPERATING PLAN, BELIEVES HAS SUFFICIENT CAPITAL RESOURCES TO FUND ANTICIPATED OPERATIONS THROUGH Q3 2019.NET LOSS TOTALED $6.5 MILLION AND $5.5 MILLION FOR Q4 OF 2017 AND 2016, RESPECTIVELY.  Full Article

Aeglea Biotherapeutics announces clinical collaboration with Merck
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Aeglea Bio Therapeutics Inc :Aeglea Biotherapeutics announces clinical collaboration with Merck to evaluate the combination of Aeglea’S AEB1102 (pegzilarginase) with Merck's Keytruda® (pembrolizumab) for the treatment of small cell lung cancer.Aeglea Bio Therapeutics Inc - ‍collaboration agreement is between Aeglea Biotherapeutics and Merck, through a subsidiary​.Aeglea Bio Therapeutics Inc - ‍additional details of collaboration were not disclosed​.Aeglea Bio Therapeutics Inc - ‍enrollment to multicenter phase 1/2 study​ is expected to begin in Q1 of 2018.  Full Article